|
See related Alimta infusion information |
|
|
|
Manufacturer |
Eli Lilly |
|
Distributor |
DKSH |
|
Contents |
Pemetrexed disodium |
|
Indications |
In combination w/ cisplatin for the treatment of chemotherapy-naive patients w/ unresectable malignant pleural mesothelioma & for the 1st-line treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) other than predominantly squamous cell histology. As monotherapy for the maintenance & 2nd-line treatment of patients w/ locally advanced or metastatic NSCLC other than predominantly squamous cell histology.
Click to view Alimta detailed prescribing infomation |
|
Dosage |
In combination w/ cisplatin 500 mg/m2 BSA IV infusion over 10 min on day 1 of each 21-day cycle. Cisplatin dose: 75 mg/m2 BSA infused over 2 hr approx 30 min after completion of pemetrexed infusion on day 1 of each 21-day cycle. As monotherapy 500 mg/m2 BSA IV infusion over 10 min on day 1 of each 21-day cycle.
Click to view Alimta detailed prescribing infomation |
|
Overdosage |
View Alimta overdosage for action to be taken in the event of an overdose. |
|
Contraindications |
Lactation. Concomitant yellow fever vaccine.
Click to view Alimta detailed prescribing infomation |
|
Special Precautions |
Monitor for myelosuppression. Reduce incidence & severity of skin reactions through pretreatment w/ corticosteroid. CrCl <45 mL/min. Avoid NSAIDs w/ long half-lives at least 5 days prior to, during or 2 days after therapy. Clinically significant 3rd space fluid. Severe dehydration. Preexisting CV risk factors. Reduce toxicity w/ concomitant folic acid & vit B12. Radiation therapy prior, during or subsequent to pemetrexed. May cause irreversible infertility in men. May impair ability to drive or operate machinery. Pregnancy. Childn <18 yr.
Click to view Alimta detailed prescribing infomation |
|
Adverse Drug Reactions |
Decreased neutrophils/granulocytes, leukocytes, Hb & platelets; conjunctivitis; GI disturbances; fatigue, fever; dehydration; sensory neuropathy, taste disturbance; elevated creatinine, decreased CrCl; elevated SGPT & SGOT; infection, rash/desquamation, pruritus, alopecia.
View ADR Monitoring Form |
|
Drug Interactions |
Nephrotoxic drugs, probenecid, penicillin, high dose NSAIDs & aspirin, live attenuated vaccines.
View more drug interactions with Alimta |
|
Pregnancy Category (US FDA) |
Category D: There is positive evidence of human foetal risk, but the benefits from use in pregnant women may be acceptable despite the risk (e.g., if the drug is needed in a life-threatening situation or for a serious disease for which safer drugs cannot be used or are ineffective). |
|
Caution For Usage |
For caution against possible variation of physical aspect of medicine... click to view Alimta detailed prescribing infomation |
|
Storage |
View Alimta storage conditions for details to ensure optimal shelf-life. |
|
Description |
View Alimta description for details of the chemical structure and excipients (inactive components). |
|
Mechanism of Action |
View Alimta mechanism of action for pharmacodynamics and pharmacokinetics details. |
|
Presentation/Packing |
|
Form |
Packing |
Photo |
|
Alimta infusion |
|
Alimta 100 mg x 1's |
|
Alimta 500 mg x 1's |
|
|
|
Manufacturer: |
Eli Lilly |
|
Distributor: |
DKSH
|
|
|
|
